言語を選択

Complement C5

Complement C5 詳細

英語名	Complement C5	市販薬剤の数	8
治験薬の数	20	ターゲットの別称	C5a，Complement Component 5，ECLZB，Anaphylatoxin C5a Analog，C5a Anaphylatoxin，C5b，C5，Prepro-C5，CPAMD4，Complement C5，C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4，C5D
研究＆開発段階	Approved

英語名	Complement C5
ターゲットの別称	C5a，Complement Component 5，ECLZB，Anaphylatoxin C5a Analog，C5a Anaphylatoxin，C5b，C5，Prepro-C5，CPAMD4，Complement C5，C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4，C5D
市販薬剤の数	8
治験薬の数	20
研究＆開発段階	Approved

Complement C5 製品リスト

属性
Protein (11)Kits (1)
製品ライブラリ
オンライン (12)
種
Human (6)Mouse (1)Rat (2)Cynomolgus (2)Rabbit (1)
タグ
His Tag (7)His Tag & Avi Tag (3)Fc Tag (1)- (1)
マーカー
Unconjugated (8)Biotin-labeled (3)- (1)

製品番号	種	発現システム	製品説明
HOT CO5-H52Ha	Human	HEK293	Human Complement C5 Protein, His Tag, low endotoxin (MALS verified)
HOT CO5-H82E9	Human	HEK293	Biotinylated Human Complement C5 Protein, His,Avitag™ (MALS verified)
HOT CO5-M52H4	Mouse	HEK293	Mouse Complement C5 Protein, His Tag
HOT CO5-R52H5	Rat	HEK293	Rat Complement C5 Protein, His Tag
CEA-B241	Human	-	Human Complement C5 ELISA Kit
CO5-H5253	Human	HEK293	Human Complement C5 Protein, Fc Tag
CO5-H52H7	Human	HEK293	Human Complement C5 (w917s) Protein, His Tag (MALS verified)
CO5-H52Hx	Human	HEK293	Human Complement C5 (R885H) Protein, His Tag
CO5-C52Hx	Cynomolgus	HEK293	Cynomolgus Complement C5 Protein, His Tag (MALS verified)
CO5-C82E3	Cynomolgus	HEK293	Biotinylated Cynomolgus Complement C5 Protein, His,Avitag™ (MALS verified)

総数量12

Complement C5バックグランド

Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Complement C5分子の別称

Complement C5,C5,CPAMD4

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Eculizumab biosimilar (CinnaGen)		Phase 3 Clinical	Cinnagen	Hemoglobinuria, Paroxysmal	詳細
Eculizumab biosimilar (IBC GENERIUM)		Phase 3 Clinical	Ibc Generium	Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal	詳細
Eculizumab biosimilar (Biocad)	BCD-148	Phase 3 Clinical	BIOCAD JSC	Hemoglobinuria, Paroxysmal	詳細
Cemdisiran	ALN-CC5; AD-62643; ALN-62643; L96	Phase 3 Clinical	Alnylam Pharmaceuticals Inc	Atypical Hemolytic Uremic Syndrome; Geographic Atrophy; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Macular Degeneration; Myasthenia Gravis; Myositis; Myositis, Inclusion Body	詳細
Tesidolumab	NOV-4; LFG-316	Phase 2 Clinical	Morphosys Ag, Novartis Pharma Ag	Geographic Atrophy; Hemoglobinuria, Paroxysmal; Macular Degeneration; Panuveitis; Rejection of renal transplantation; Uveitis, Intermediate; Uveitis, Posterior; Wet Macular Degeneration	詳細
IM-101	IM-101	Phase 2 Clinical	ImmunAbs Inc	Autoimmune Diseases; Myasthenia Gravis	詳細
ABBV-6628	ABBV-6628	Phase 2 Clinical	Abbvie Inc	Geographic Atrophy; Macular Degeneration	詳細
OCUL-101	OCUL101	Phase 2 Clinical	Shenzhen Oukejian Biomedical Technology Co Ltd	Diabetic macular oedema; Geographic Atrophy; Macular Degeneration; Retinal Neovascularization	詳細
KRIYA-825	KRIYA-825; VV-14295	Phase 2 Clinical	Kriya Therapeutics Inc	Geographic Atrophy	詳細
LP-005	LP-005; RX-001	Phase 2 Clinical	Longbio Pharma (Suzhou) Co Ltd	Amyotrophic Lateral Sclerosis; C3 glomerulopathy; Carcinoma, Non-Small-Cell Lung; Complement-Mediated Diseases; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Myasthenia Gravis; Periodontal Diseases; Peripheral Nervous System Diseases; Thrombotic Microangiopathies	詳細
Vensobafusp alfa	P014; KP-104	Phase 2 Clinical	Kira Pharmaceuticals LLC	Glomerulonephritis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Erythematosus, Systemic; Thrombotic Microangiopathies	詳細
Omoprubart	CAN-106	Phase 2 Clinical	Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd	Genetic Diseases, Inborn; Hemoglobinuria, Paroxysmal	詳細
ALXN-5500	ALXN-5500	Phase 1 Clinical	Alexion Pharmaceuticals Inc	Hemoglobinuria, Paroxysmal	詳細
RLYB-116	RLYB-116	Phase 1 Clinical	Affibody Ab, Swedish Orphan Biovitrum (Sobi)	Autoimmune Diseases; Hematologic Diseases; Immune System Diseases; Inflammation	詳細
SYH-2061	SYH2061; SYH-2061	Phase 1 Clinical	CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd	Complement-Mediated Diseases; Glomerulonephritis, IGA; Nephrosis	詳細
NM3086	NM3086; NM-3086	Phase 1 Clinical	NovelMed Therapeutics Inc	Hemoglobinuria, Paroxysmal	詳細
Eculizumab biosimilar (Turgut Ardika)	TUR03; TUR-03	Phase 1 Clinical	Turgut Ardika Pty Ltd		詳細
EA-5	EA-5; EA5	Phase 1 Clinical	Shandong Lanyi Pharmaceutical Technology Co Ltd	Antiphospholipid Syndrome; Hemoglobinuria, Paroxysmal; Kidney Diseases; Myasthenia Gravis; Thrombotic Microangiopathies	詳細
RBD-7007	RBD-7007	Phase 1 Clinical	Suzhou Ribo Life Science Co Ltd	Glomerulonephritis, IGA	詳細
eculizumab biosimilar(Isu Abxis)	ISU-305	Phase 1 Clinical	Isu Abxis Co Ltd	Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Avacincaptad pegol sodium	ARC-1905; ARC-187	Approved	Archemix Corp	Zimura, Izervay	United States	Macular Degeneration; Geographic Atrophy	Iveric Bio Inc, Astellas Pharma Inc	2023-08-04	Geographic Atrophy; Macular Degeneration; Polypoidal choroidal vasculopathy	詳細
Zilucoplan Sodium	RA-101495-SC; RA-101495; ZLP-AI	Approved	Ra Pharmaceuticals Inc, Ucb Sa	ZILBRYSQ, Zilbrysq, 卓倍可	Japan	Myasthenia Gravis	Ucb Japan Co Ltd	2023-09-25	Amyotrophic Lateral Sclerosis; Coronavirus Disease 2019 (COVID-19); Hemoglobinuria, Paroxysmal; Muscular Diseases; Myasthenia Gravis	詳細
Crovalimab	RO-7112689/F01; SKY-59; RO711269; RO-711269; RG-6107; CH-7092230; RO-7092230; RO-7112689	Approved	Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd	派圣凯, Piasky	Mainland China	Hemoglobinuria, Paroxysmal	Roche Pharma (Schweiz) Ag, Roche (China) Holding Ltd, Genentech Inc	2024-02-06	Anemia, Sickle Cell; Antiphospholipid Syndrome; Atypical Hemolytic Uremic Syndrome; Guillain-Barre Syndrome; Hemoglobinuria, Paroxysmal	詳細
Ravulizumab	ALXN-1810; ALXN-1210	Approved	Alexion Pharmaceuticals Inc, Xencor Inc	Ultomiris, 伟立瑞	United States	Hemoglobinuria, Paroxysmal	Alexion Pharmaceuticals Inc	2018-12-21	Acute Kidney Injury; Acute Lung Injury; Amyotrophic Lateral Sclerosis; Atypical Hemolytic Uremic Syndrome; Coronavirus Disease 2019 (COVID-19); Delayed Graft Function; Dermatomyositis; Glomerulonephritis, IGA; Heart Diseases; Hemoglobinuria, Paroxysmal; Immunoglobulin A Vasculitis Associated Nephritis; Kidney Diseases; Kidney Failure, Chronic; Lupus Nephritis; Myasthenia Gravis; Neuromyelitis Optica; Pneumonia, Viral; Purpura, Schoenlein-Henoch; Rejection of renal transplantation; Renal Insufficiency, Chronic; Respiratory Distress Syndrome, Adult; Thrombotic Microangiopathies	詳細
Eculizumab	LEX-98; h-5G1.1; 5G1-1; HAL-1	Approved	Alexion Pharmaceuticals Inc	Soliris, 舒立瑞	United States	Hemoglobinuria, Paroxysmal	Alexion Pharmaceuticals Inc	2007-03-16	Anemia, Hemolytic, Autoimmune; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Asthma; Atypical Hemolytic Uremic Syndrome; Delayed Graft Function; Diabetes Mellitus; End Stage Liver Disease; Glomerulonephritis, Membranoproliferative; Guillain-Barre Syndrome; HELLP Syndrome; Hemoglobinuria, Paroxysmal; Infant, Newborn, Diseases; Kidney Failure, Chronic; Macular Degeneration; Myasthenia Gravis; Nasopharyngeal Carcinoma; Neuromyelitis Optica; Parturition; Pre-Eclampsia; Rejection of renal transplantation; Rejection of organ transplantation; Thrombocytopenia; Urea Cycle Disorders, Inborn; Vagus Nerve Diseases	詳細
Pozelimab	REGN-3918	Approved	Regeneron Pharmaceuticals Inc	VEOPOZ	United States	Protein-Losing Enteropathies	Regeneron Pharmaceuticals Inc	2023-08-18	Geographic Atrophy; Hemoglobinuria, Paroxysmal; Myasthenia Gravis; Protein-Losing Enteropathies	詳細
Eculizumab biosimilar (Amgen)	ABP-959	Approved	Amgen Inc	BKEMV	United States	Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome	Amgen Inc	2024-05-28	Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal	詳細
Eculizumab biosimilar (Samsung Bioepis)	SB-12; AM004; AMT-904; SB12	Approved	Samsung Bioepis Co Ltd	Epysqli, EPYSQLI	EU	Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal	Samsung Bioepis Nl Bv	2023-05-26	Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal	詳細

レビュー

1***32022-08-10
0評価
Cynomolgus Complement C5 Protein, His Tag (MALS verified)
I tried to express this product myself and it didn’t work, so I purchased ACRO’s products for antibody screening. The binding activity is very good and method establishment is also going very smoothly. There is also complete technical support available to help us solve any problems that arise during our experiments.